Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
October 2018
-
Media ReleaseNovartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burdenLutathera treatment was associated with an ~80% reduction in the estimated risk of tumor progression or death vs comparator, regardless of baseline liver tumor burden[1] Lutathera treatment was…
-
Featured NewsNovartis Financial Results – Q3 2018Today, Novartis CEO Vas Narasimhan announced the company’s financial results for the third quarter of 2018.
-
Key ReleaseNovartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platformsNovartis to acquire Endocyte to accelerate development of innovative radioligand technology for treating cancer Acquisition would add 177Lu-PSMA-617, a potential first-in-class…
-
Key ReleaseNovartis a enregistré, au troisième trimestre, une forte croissance et fait preuve d'une innovation dynamique, incluant des plateformes thérapeutiques avancées pour soutenir la croissance futureHausse du chiffre d'affaires net de 6% (tcc[1], +3% USD), stimulée principalement par: Cosentyx, qui a progressé à USD 750 millions (+37% tcc) grâce à une forte croissance en volume dans toutes…
-
Key ReleaseNovartis erzielt im dritten Quartal starkes Wachstum und treibt Innovationen wie fortschrittliche Therapieplattformen voran, um das zukünftige Wachstum zu beschleunigenDer Nettoumsatz steigt um 6% (kWk[1], +3% USD), vor allem dank folgender Beiträge: Cosentyx erzielt mit starken Volumenzuwächsen in allen Indikationen einen Umsatz von USD 750 Millionen (+37% kWk…
-
Key ReleaseNovartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growthNet sales grew 6% (cc[1], +3% USD) mainly driven by: Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indications Entresto more than doubled to USD 271 million (+113…
-
Media ReleaseNovartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritisData from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] …
-
Media ReleaseSandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient accessGlobal resolution secures patient access to Sandoz biosimilar Hyrimoz® (adalimumab)[1] for the reference medicine Humira®** Resolution paves way for 2018 launch in key European markets and…
-
Media ReleaseNovartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosisTopline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (…
-
Story From Our LabsWomen in Science: Marjorie Eiref
Marjorie Eiref, Head of Operations for Neuroscience Research at Novartis, describes how her family medical history has impacted her career.
-
Media ReleaseBreadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden33 abstracts from the leading MS portfolio include data for Gilenya® (fingolimod), and investigational drugs siponimod (BAF312) and ofatumumab (OMB157) New research will be presented on…
-
Media ReleaseNovartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN studyData published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or…
Pagination
- ‹ Previous page
- 1
- …
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- …
- 152
- › Next page